Author:
Takasaki Kazuki,Ichinose Takayuki,Miyagawa Yuko,Fukui Shiho,Hashimoto Kei,Nishida Haruka,Takahashi Yuko,Hiraike Haruko,Saito Koji,Sasajima Yuko,Nagasaka Kazunori
Abstract
Abstract
Background
Granulosa cell tumors (GCTs) account for approximately 2% of ovarian malignancies and are considered a rare type of ovarian cancer. GCTs are characterized by irregular genital bleeding after menopause due to female hormone production as well as late recurrence around 5–10 years after initial treatment. In this study, we investigated two cases of GCTs to find a biomarker that can be used to evaluate the treatment and predict recurrence.
Case presentation
Case 1 was a 56-year-old woman who presented to our hospital with abdominal pain and distention. An abdominal tumor was found, and GCTs were diagnosed. Serum vascular endothelial growth factor (VEGF) levels decreased after surgery. Case 2 involved a 51-year-old woman with refractory GCTs. Carboplatin–paclitaxel combination therapy and bevacizumab were administered after the tumor resection. After chemotherapy, a decline in VEGF levels was observed, but serum VEGF levels increased again with disease progression.
Conclusions
VEGF expression may be of clinical importance in GCTs as a clinical biomarker for disease progression, which may be used to determine the efficacy of bevacizumab against GCTs.
Funder
Grant-in-Aid for Scientific Research from the Ministry of Education
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Oncology
Reference17 articles.
1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180–9.
2. Barrena Medel NI, Herzog TJ, Wright JD, Lewin SN. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. Anticancer Res. 2010;30:4767–8.
3. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009;114:431–6.
4. Wang WC, Lai YC. Molecular pathogenesis in granulosa cell tumor is not only due to somatic FOXL2 mutation. J Ovarian Res. 2014;7:88.
5. Wang D, Xiang Y, Wu M, Shen K, Yang J, Huang H, et al. Clinicopathological characteristics and prognosis of adult ovarian granulosa cell tumor: a single-institution experience in China. Onco Targets Ther. 2018;11:1315–22.